Literature DB >> 17388946

Nodule formation and desmoplasia in medulloblastomas-defining the nodular/desmoplastic variant and its biological behavior.

Charles S McManamy1, Jane Pears, Claire L Weston, Zoltan Hanzely, James W Ironside, Roger E Taylor, Richard G Grundy, Steven C Clifford, David W Ellison.   

Abstract

Among the variants of medulloblastoma in the current WHO classification of nervous system tumors, the desmoplastic variant, which has been reported to constitute 5%-25% of pediatric medulloblastomas, is defined by its nodular collections of neurocytic cells bounded by desmoplastic internodular zones. We have studied the frequency, morphological features and biological behavior of medulloblastomas in two contemporaneous SIOP/UKCCSG trial cohorts of children with medulloblastomas, CNS9102 (n = 315) and CNS9204 (n = 35), focusing on tumors with nodular and desmoplastic phenotypes. In children aged 3-16 years (CNS9102), the nodular/desmoplastic medulloblastoma represented 5% of all tumors, while in infants aged <3 years (CNS9204) this variant represented 57% of medulloblastomas. Using iFISH to detect molecular cytogenetic abnormalities in medulloblastomas with a nodular architecture, we demonstrated distinct genetic profiles in desmoplastic and non-desmoplastic (classic and anaplastic) tumors; in particular, abnormalities of chromosome 17 occurred in the latter, but not the former. Significantly different outcomes were demonstrated for classic, nodular/desmoplastic and large cell/anaplastic medulloblastomas in both cohorts. In conclusion, the nodular/desmoplastic medulloblastoma appears to have clinical, genetic and biological characteristics that set it apart from other variants of this tumor.

Entities:  

Mesh:

Year:  2007        PMID: 17388946     DOI: 10.1111/j.1750-3639.2007.00058.x

Source DB:  PubMed          Journal:  Brain Pathol        ISSN: 1015-6305            Impact factor:   6.508


  41 in total

1.  Value and limitations of diffusion-weighted imaging in grading and diagnosis of pediatric posterior fossa tumors.

Authors:  J L Jaremko; L B O Jans; L T Coleman; M R Ditchfield
Journal:  AJNR Am J Neuroradiol       Date:  2010-06-10       Impact factor: 3.825

2.  Magnetic resonance imaging spectrum of medulloblastoma.

Authors:  Julia Fruehwald-Pallamar; Stefan B Puchner; Andrea Rossi; Maria L Garre; Armando Cama; Claus Koelblinger; Anne G Osborn; Majda M Thurnher
Journal:  Neuroradiology       Date:  2011-01-29       Impact factor: 2.804

3.  Heterogeneity of familial medulloblastoma and contribution of germline PTCH1 and SUFU mutations to sporadic medulloblastoma.

Authors:  Ingrid Slade; Anne Murray; Sandra Hanks; Ajith Kumar; Lisa Walker; Darren Hargrave; Jenny Douglas; Charles Stiller; Louise Izatt; Nazneen Rahman
Journal:  Fam Cancer       Date:  2011-06       Impact factor: 2.375

4.  Embryonal central nervous system neoplasms arising in infants and young children: a pediatric brain tumor consortium study.

Authors:  Roger E McLendon; Adesina Adekunle; Veena Rajaram; Mehmet Koçak; Susan M Blaney
Journal:  Arch Pathol Lab Med       Date:  2011-08       Impact factor: 5.534

5.  Biological characterization of the UW402, UW473, ONS-76 and DAOY pediatric medulloblastoma cell lines.

Authors:  Ricardo Bonfim-Silva; Karina Bezerra Salomão; Thais Valéria Costa de Andrade Pimentel; Camila Cristina Branquinho de Oliveira Menezes; Patrícia Vianna Bonini Palma; Aparecida Maria Fontes
Journal:  Cytotechnology       Date:  2019-07-26       Impact factor: 2.058

6.  Two tumor suppressors, p27Kip1 and patched-1, collaborate to prevent medulloblastoma.

Authors:  Olivier Ayrault; Frederique Zindy; Jerold Rehg; Charles J Sherr; Martine F Roussel
Journal:  Mol Cancer Res       Date:  2009-01       Impact factor: 5.852

7.  Treatment of early childhood medulloblastoma by postoperative chemotherapy and deferred radiotherapy.

Authors:  Stefan Rutkowski; Nicolas Ulrich Gerber; Katja von Hoff; Astrid Gnekow; Udo Bode; Norbert Graf; Frank Berthold; Günter Henze; Johannes E A Wolff; Monika Warmuth-Metz; Niels Soerensen; Angela Emser; Holger Ottensmeier; Frank Deinlein; Paul-Gerhardt Schlegel; Rolf-Dieter Kortmann; Torsten Pietsch; Joachim Kuehl
Journal:  Neuro Oncol       Date:  2008-09-25       Impact factor: 12.300

8.  Global analysis of the medulloblastoma epigenome identifies disease-subgroup-specific inactivation of COL1A2.

Authors:  Jennifer A Anderton; Janet C Lindsey; Meryl E Lusher; Richard J Gilbertson; Simon Bailey; David W Ellison; Steven C Clifford
Journal:  Neuro Oncol       Date:  2008-07-29       Impact factor: 12.300

9.  Medulloblastomas: a correlative study of MIB-1 proliferation index along with expression of c-Myc, ERBB2, and anti-apoptotic proteins along with histological typing and clinical outcome.

Authors:  Prasenjit Das; Tarun Puri; Vaishali Suri; M C Sharma; B S Sharma; Chitra Sarkar
Journal:  Childs Nerv Syst       Date:  2009-05-15       Impact factor: 1.475

10.  Amplification and overexpression of Hsa-miR-30b, Hsa-miR-30d and KHDRBS3 at 8q24.22-q24.23 in medulloblastoma.

Authors:  Yuan Lu; Sarra L Ryan; David J Elliott; Graham R Bignell; P Andrew Futreal; David W Ellison; Simon Bailey; Steven C Clifford
Journal:  PLoS One       Date:  2009-07-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.